Patents by Inventor Craig Rosen
Craig Rosen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9416185Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.Type: GrantFiled: April 3, 2014Date of Patent: August 16, 2016Assignee: TEVA BIOPHARMACEUTICALS USA, INC.Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
-
Patent number: 9403905Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: May 15, 2014Date of Patent: August 2, 2016Assignee: HUMAN GENOME SCIENCES, INC.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Publication number: 20140342405Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: May 15, 2014Publication date: November 20, 2014Applicant: Human Genome Sciences, Inc.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Publication number: 20140315250Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.Type: ApplicationFiled: April 3, 2014Publication date: October 23, 2014Applicant: TEVA Biopharmaceuticals USA, Inc.Inventors: Rodger SMITH, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
-
Patent number: 8784809Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: January 24, 2013Date of Patent: July 22, 2014Assignee: Human Genome Sciences, Inc.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Patent number: 8728482Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.Type: GrantFiled: August 14, 2012Date of Patent: May 20, 2014Assignee: TEVA Biopharmaceuticals USA, Inc.Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
-
Publication number: 20130323240Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).Type: ApplicationFiled: August 8, 2013Publication date: December 5, 2013Applicant: TEVA Biopharmaceuticals USA, Inc.Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
-
Publication number: 20130309232Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: January 24, 2013Publication date: November 21, 2013Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Publication number: 20130253979Abstract: A computer implemented method for managing risk, which can include determining an organizational impact score from an aggregate of scenario impact scores and storing the organizational impact score in a memory of the computer. Some embodiments include calculating a likelihood score based upon an analysis of threats, imminence of each threat, and a likelihood associated with each threat, and storing the likelihood score in a memory of the computer. In some embodiments, an organizational maturity score is determined based on the ability of the organization to mitigate the actions of a potential threat and recover from a given scenario, and the organizational maturity score is stored in a memory of the computer. Some embodiments include calculating a Risk Index using a processor of the computer wherein the Risk Index equals the impact score multiplied by the likelihood score and divided by the maturity score.Type: ApplicationFiled: March 13, 2013Publication date: September 26, 2013Applicant: Pacific Gas and Electric CompanyInventors: Ramsey Williams, James Sample, Craig Rosen, Suneel Sundar, Richard Jones, Eddie Borrero
-
Patent number: 8524869Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).Type: GrantFiled: March 22, 2010Date of Patent: September 3, 2013Assignee: Teva Biopharmaceuticals USA, Inc.Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
-
Publication number: 20120308480Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.Type: ApplicationFiled: August 14, 2012Publication date: December 6, 2012Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
-
Patent number: 8263743Abstract: Disclosed are humanized antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.Type: GrantFiled: November 13, 2008Date of Patent: September 11, 2012Assignee: Teva Biopharmaceuticals USA, Inc.Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
-
Publication number: 20120100074Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).Type: ApplicationFiled: March 22, 2010Publication date: April 26, 2012Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
-
Publication number: 20100143360Abstract: Disclosed is a human VEGF2 polypeptide and DNA(RNA) encoding such VEGF2 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist against such polypeptide. Also disclosed is a method of using such polypeptide for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antagonists to inhibit tumor growth, inflammation and to treat diabetic retinopathy, rheumatoid arthritis and psoriasis. Diagnostic methods for detecting mutations in the VEGF2 coding sequence and alterations in the concentration of VEGF2 protein in a sample derived from a host are also disclosed.Type: ApplicationFiled: October 24, 2008Publication date: June 10, 2010Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Craig Rosen, Jing-Shan Hu, Liang Cao
-
Publication number: 20090280116Abstract: Disclosed are humanized antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.Type: ApplicationFiled: November 13, 2008Publication date: November 12, 2009Inventors: Rodger SMITH, Palanisamy KANAKARAJ, Viktor ROSCHKE, Craig ROSEN
-
Publication number: 20080226586Abstract: The present invention concerns a member of the human chemokine CC protein family. In particular, isolated nucleic acid molecules are provided encoding the chemokine ?-15 protein. Chemokine ?-15 polypeptides are also provided. The invention further concerns diagnostic methods for detecting thymus disorders and therapeutic methods for modulating bone marrow cell proliferation and differentiation.Type: ApplicationFiled: October 2, 2006Publication date: September 18, 2008Applicant: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Brent Kreider, Craig Rosen
-
Publication number: 20080163647Abstract: A jewelry arrangement having a mounting, a main gemstone positioned in the mounting, and a plurality of secondary gemstone positioned in the mounting underneath the main gemstone. The main gemstone can have a crown with a table and a pavilion, wherein the table can be positioned adjacent and at a first distance from the plurality of secondary gemstones. The main gemstone can also have a plurality of side which converge toward each other and have a plurality of facets. The sides can coverage towards a top which can be a second distance from the secondary gemstones such that the first distance is less than the second distance. An optical illusion can be created by orienting a main gemstone above a first number of secondary gemstones and configuring the main gemstone so that when the secondary gemstones are viewed through the main gemstone, a second number of secondary gemstones is visible such that the second number is greater than the first number.Type: ApplicationFiled: January 5, 2007Publication date: July 10, 2008Inventor: Ronald Craig Rosen
-
Publication number: 20080103090Abstract: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating cancer and other hyperproliferative diseases and disorders. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.Type: ApplicationFiled: March 19, 2007Publication date: May 1, 2008Applicant: Human Genome Sciences, Inc.Inventors: Craig Rosen, Steven Ruben
-
Publication number: 20080058247Abstract: Receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing receptor polypeptides and polynucleotides in the design of protocols for the treatment of diseases and diagnostic assays for such conditions.Type: ApplicationFiled: August 1, 2007Publication date: March 6, 2008Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Craig Rosen, Reiner Gentz
-
Publication number: 20080057004Abstract: Disclosed are fusion proteins that include albumin fused to a polypeptide that has insulin activity. The fusion proteins may include albumin fused to insulin or an insulin analog. In particular, the fusions proteins may include albumin fused to a single chain insulin analog. The fusion proteins may exhibit extended insulin activity in vivo or in vitro relative to insulin that is not fused to albumin. The fusion proteins may be formulated as aerosol compositions.Type: ApplicationFiled: August 7, 2007Publication date: March 6, 2008Inventors: Adam Bell, Craig Rosen, Indrajit Sanyal, Qinghai Zhao